276 related articles for article (PubMed ID: 12186514)
1. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
[TBL] [Abstract][Full Text] [Related]
2. Summaries for patients. Can maintenance therapy for opportunistic infections in HIV-infected people be stopped safely?
Ann Intern Med; 2002 Aug; 137(4):I34. PubMed ID: 12186538
[No Abstract] [Full Text] [Related]
3. Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy.
Rossi M; Flepp M; Telenti A; Schiffer V; Egloff N; Bucher H; Vernazza P; Bernasconi E; Weber R; Rickenbach M; Furrer H;
Swiss Med Wkly; 2001 Aug; 131(31-32):471-7. PubMed ID: 11641970
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
6. AIDS related opportunistic infections, going but not gone.
Samuel R; Bettiker RL; Suh B
Arch Pharm Res; 2002 Jun; 25(3):215-28. PubMed ID: 12135090
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcosis in HIV infection of man: an epidemiological and immunological indicator?
Arastéh K; Staib F; Grosse G; Futh U; L'Age M
Zentralbl Bakteriol; 1996 Jul; 284(2-3):153-63. PubMed ID: 8837378
[TBL] [Abstract][Full Text] [Related]
9. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
11. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.
Shafran SD; Mashinter LD; Phillips P; Lalonde RG; Gill MJ; Walmsley SL; Toma E; Conway B; Fong IW; Rachlis AR; Williams KE; Garber GE; Schlech WF; Smaill F; Pradier C
Ann Intern Med; 2002 Nov; 137(9):734-7. PubMed ID: 12416943
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.
Furrer H; Telenti A; Rossi M; Ledergerber B
AIDS; 2000 Jul; 14(10):1409-12. PubMed ID: 10930156
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
[TBL] [Abstract][Full Text] [Related]
14. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Lange CG; Woolley IJ; Brodt RH
Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.
Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet AM; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C;
AIDS; 2001 Jan; 15(1):23-31. PubMed ID: 11192865
[TBL] [Abstract][Full Text] [Related]
16. Update on opportunistic infections.
Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
[TBL] [Abstract][Full Text] [Related]
17. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
18. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
Kirk O; Lundgren JD; Pedersen C; Nielsen H; Gerstoft J
AIDS; 1999 Sep; 13(13):1647-51. PubMed ID: 10509565
[TBL] [Abstract][Full Text] [Related]
19. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team.
Aberg JA; Williams PL; Liu T; Lederman HM; Hafner R; Torriani FJ; Lennox JL; Dube MP; MacGregor RR; Currier JS;
J Infect Dis; 2003 Apr; 187(7):1046-52. PubMed ID: 12660918
[TBL] [Abstract][Full Text] [Related]
20. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
Green H; Hay P; Dunn DT; McCormack S;
HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
